» Articles » PMID: 27940335

Comparison Between the Kansas City Cardiomyopathy Questionnaire and New York Heart Association in Assessing Functional Capacity and Clinical Outcomes

Overview
Journal J Card Fail
Date 2016 Dec 13
PMID 27940335
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: The Kansas City Cardiomyopathy Questionnaire (KCCQ) has emerged as a patient-centered heart failure-specific health status measure. It currently lacks routine and widespread use in clinical practice and trials. The purpose of this study was to examine the correlation between KCCQ and cardiopulmonary exercise testing (CPET) parameters and clinical outcomes, compared with the New York Heart Association functional classification (NYHA).

Methods And Results: We performed a single-centered observational analysis of 432 patients who presented to the Heart Failure Department, completed the KCCQ, and underwent CPET. The 1-year clinical outcome assessed was a composite of mortality, heart failure hospitalization, and need for heart transplantation or left ventricular assist device. In the KCCQ, the physical limitation domain had a correlation with peak VO similar to NYHA (r = 0.48; P < .001; and r = -0.48; P < .001; respectively), and slightly better correlation with ventilatory threshold (r = 0.42; P < .001; and r = -0.40; P < .001; respectively). According to model validation, the KCCQ physical limitation domain and NYHA were similar predictors of peak VO (r = 0.229; and r = 0.227; respectively). KCCQ predicted the specified 1-year clinical outcome (hazard ratio 0.75, 95% confidence interval 0.69-0.82; P < .001) and provided incremental predictive ability when added to a model that included NYHA, with a net reclassification index of 76.1% (P < .001).

Conclusions: KCCQ and NYHA provide similar assessment of functional capacity. KCCQ predicts 1-year clinical outcomes, providing incremental value over NYHA. These findings support its routine use in clinical care, as well as its potential to serve as a measure in clinical trials.

Citing Articles

Cardiopulmonary exercise capacity markers and their link to symptom burden in patients at risk for heart failure with non-reduced ejection fraction.

Kwast S, Hoffmann J, Pokel C, Falz R, Schulze A, Schroter T Sci Rep. 2025; 15(1):8940.

PMID: 40089637 DOI: 10.1038/s41598-025-94172-1.


Current status of outpatient heart failure management in Egypt and recommendations for the future.

Hassanein M, Tageldien A, Badran H, Samir H, Elshafey W, Hassan M ESC Heart Fail. 2023; 10(5):2788-2796.

PMID: 37559352 PMC: 10567665. DOI: 10.1002/ehf2.14485.


Evaluating the Implementation of Patient-Reported Outcomes in Heart Failure Clinic: A Qualitative Assessment.

Brown-Johnson C, Calma J, Amano A, Winget M, Harris S, Vilendrer S Circ Cardiovasc Qual Outcomes. 2023; 16(5):e009677.

PMID: 37114990 PMC: 10192029. DOI: 10.1161/CIRCOUTCOMES.122.009677.


Validation of the Portuguese Version of the Kansas City Cardiomyopathy Questionnaire-12.

Dos Reis M, Nascimento J, de Andrade G, Costa A, Takada J, Mansur A J Cardiovasc Dev Dis. 2023; 10(4).

PMID: 37103041 PMC: 10144930. DOI: 10.3390/jcdd10040162.


Testosterone and quality of life in patients with dilated cardiomyopathy.

Diaconu R, Neagoe O, Mirea O, Tieranu E, Mustafa R, Balseanu T Discoveries (Craiova). 2022; 10(3):e156.

PMID: 36540088 PMC: 9757918. DOI: 10.15190/d.2022.15.